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Abstract
The early detection of bladder cancer (BCa) is pivotal for successful patient treatment and management. Through genomic
and proteomic studies, we have identified a number of bladder cancer-associated biomarkers that have potential clinical
utility. In a case-control study, we examined voided urines from 127 subjects: 64 tumor-bearing subjects and 63 controls.
The urine concentrations of the following proteins were assessed by enzyme-linked immunosorbent assay (ELISA); C-C motif
chemokine 18 (CCL18), Plasminogen Activator Inhibitor 1 (PAI-1) and CD44. Data were compared to a commercial ELISA-
based BCa detection assay (BTA-Trak) and voided urinary cytology. We used analysis of the area under the curve of
receiver operating characteristic curves to compare the ability of CCL18, PAI-1, CD44, and BTA to detect BCa in voided urine
samples. Urinary concentrations of CCL18, PAI-1, and BTA were significantly elevated in subjects with BCa. CCL18 was the
most accurate biomarker (AUC; 0.919; 95% confidence interval [CI], 0.8704-0.9674). Multivariate regression analysis
highlighted CCL18 (OR; 18.31; 95% CI, 4.95-67.70, p,0.0001) and BTA (OR; 6.43; 95% CI, 1.86-22.21, p=0.0033) as
independent predictors of BCa in voided urine samples. The combination of CCL18, PAI-1 and CD44 improved the area
under the curve to0.938. Preliminary results indicate that CCL18 was a highly accurate biomarker for BCa detection in this
cohort. Monitoring CCL18 in voided urine samples has the potential to improve non-invasive tests for BCa diagnosis.
Furthermore using the combination of CCL18, PAI-1 and CD44 may make the model more robust to errors to detect BCa
over the individual biomarkers or BTA.
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Introduction
The early detection of bladder cancer (BCa) significantly
improves the probability of successful patient treatment and
management. The development of molecular assays that can
diagnose the disease accurately, or that can augment current
methods of evaluation, would be a significant advance. A
molecular assay that was applicable to non-invasively obtained
body fluids, would facilitate not only diagnosis of at risk patients,
but also asymptomatic screening, monitoring disease recurrence
and response to treatment. The advent of advanced proteomics
and genomics technologies, and associated bioinformatics devel-
opment, is bringing these goals into focus.
The gold standard for diagnosing BCa involves cystoscopic
examination of the bladder along with biopsy and pathologic
evaluation of a bladder lesion. Voided urinary cytology (VUC)
remains as the go-to non-invasive adjunct to cystoscopy in the
detection of BCa. While VUC has a specificity of .93%, its
sensitivity is quite dismal at 25–40%, especially for low-grade and
low-stage tumors [1,2]. The need for more accurate urinary
biomarkers for the detection of BCa is evident. A number of
molecular tests have been developed to detect bladder tumors,
including bladder tumor antigen (BTA) [3], nuclear matrix protein
22 (NMP-22) [4], ImmunoCyt and Urovysion [5]. Unfortunately
due to their limited sensitivity and/or specificity, none of these
assays have been proven accurate enough to replace cystoscopy or
VUC. Thus there are no urine-based BCa tests that dominate the
field to date. The inadequate power of single biomarkers may
partly explain why detecting BCa using urinalysis remains a
challenge. There needs to be an evolution towards tests that
monitor multiple biomarkers in order to achieve the desired
diagnostic accuracy.
The advent of new high-throughput genomic and proteomic
techniques is driving biomarker discovery forward, and we have
employed these techniques in a series of experiments [6,7,8] from
which we have derived both nucleic acid and protein biomarker
panels that facilitate non-invasive detection of BCa with unprec-
edented accuracy. Further selection and validation of 14 proteins
from the proteomic studies, and some protein products from the
genomic signature, was based on statistical ranking of association
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study, we investigated whether the monitoring of some of these
targets using immune-based detection assays could confirm the
potential clinical utility of a non-invasive diagnostic test. Using
ELISA assays, we monitored three target proteins (C-C motif
chemokine 18, CCL18; Plasminogen Activator Inhibitor 1, PAI-1;
and CD44) in urine samples from a cohort of 127 subjects, and
compared diagnostic performance to that obtained using the
commercial BTA-Trak assay and VUC.
Results
Demographic, clinical and pathologic characteristics of the
cohort are presented in Table 1. Only 28% of the cancer cohort
had a positive VUC whereas VUC specificity was 98%. Urinary
CCL18 and PAI-1 were undetectable in the majority of subjects
with no evidence of BCa. Both BTA and CD44 were detected in
samples from both tumor-bearing and control groups. Mean
urinary levels (Table 2) of CCL18 (637.39 pg/ml vs. 4.81 pg/ml,
p , 0.0001), PAI-1 (6.82 ng/ml vs. 0.06 ng/ml, p,0.0001), and
BTA 1630.55 U/ml vs. 14.54 U/ml, p,0.0001) were significantly
higher in subjects with BCa compared to subjects with no evidence
of BCa. Mean urinary CD44 was elevated in subjects without BCa
compared to subjects with BCa (117.22 ng/ml vs. 53.09 ng/ml,
p,0.0001). ELISA data are presented in a boxplot figure
(Figure 1).
The ability of the test biomarkers to predict the presence of BCa
was analyzed using nonparametric ROC analyses, according to
National Cancer Institute guidelines [9]. Based on the area under
the ROC curve (AUROC), we determined Youden Index cutoff
values to maximize the sum of sensitivity and specificity. Urinary
CCL18 was the most accurate biomarker with an area under the
curve of 0.919 (95% CI: 0.8704-0.9674). Using the Youden Index
cutoff value (Figure 2), urinary CCL18 provided a sensitivity of
88%, specificity of 86%, positive predictive value of 86% and
negative predictive value of 87%. PAI-1 was a less accurate
biomarker for BCa detection (area under the curve: 0.686; 95%
CI: 0.6119-0.7601). Using the Youden Index cutoff value
(Figure 2), urinary PAI-1 analyses revealed a sensitivity of 42%,
specificity of 100%, positive predictive value of 100% and negative
predictive value of 63%. Elevated levels of urinary CD44 were not
indicative of BCa (area under the curve: 0.488; 95% CI: 0.383-
0.5937). BTA served as our positive reference assay and was noted
to have an AUROC of 0.818 (95% CI: 0.74-0.90, Figure 2).
Using the Youden Index cutoff value, urinary BTA provided a
sensitivity of 80%, specificity of 84%, positive predictive value of
84% and negative predictive value of 80%.
In multivariate logistic regression analysis that adjusted for the
effects of age and race, elevated CCL18 (OR: 18.31; 95% CI:
4.95-67.70; p,0.0001), elevated BTA (OR: 6.43; 95% CI: 1.86-
22.21; p=0.0033) and reduced urinary levels of CD44 (OR: 0.039;
95% CI: 0.004-0.35; p=0.0036) were associated with BCa in
voided urine samples (Table 3).
As stated earlier, single biomarkers fall short by not taking into
consideration the complexity of heterogeneous tumors, thus a
multiplex assay to detect a panel of biomarkers may prove to be
beneficial. Utilizing the Youden Index cutoff values for CCL18,
PAI-1 and CD44, these biomarkers were combined and analyzed
(Figure 3). The combination of CCL18, PAI-1 and CD44 (area
under the curve: 0.938) achieved a sensitivity of 86%, specificity of
89%, positive predictive value of 89% and negative predictive
value of 86%.
Discussion
Using novel approaches [6–8], we have identified a preliminary
diagnostic signature of 14 biomarkers related to BCa. In this study,
we report our findings of three of these 14 biomarkers.
Increased urinary levels of CCL18, PAI-1, and BTA, were
significantly associated with the presence of BCa. In univariate
analyses, CCL18 proved to be the marker most associated with
BCa (AUC; 0.919; 95% CI, 0.8704-0.9674), with an overall
positive predictive value of 86%, and a negative predictive value of
87%. Multivariate regression analysis highlighted CCL18 (OR;
18.31; 95% CI, 4.95-67.70, p,0.0001), BTA-Trak (OR; 6.43;
95% CI, 1.86-22.21, p=0.0033) and CD44 (OR; 0.039; 95% CI,
0.004-0.35, p=0.0036) as independent variables in the detection
Table 1. Demographic and clinicopathologic characteristics
of the study cohort.
Non-cancer (%)
N=63
Cancer (%)
N=64
Median Age (range, y) 60 (30–81) 69.5 (22–90)
Male: Female ratio 55: 8 55: 9
Race
White 41 (65) 58 (91)
African American 8 (13) 0 (0)
Other 14 (22) 6 (9)
Tobacco use 25 (40) 54 (84)
Gross hematuria 0 (0) 47 (73)
Suspicious/positive cytology 1 (2) 18 (28)
Median follow-up (months) 11.5 12.0
Clinical stage
Tisˆ n/a 6 (9)
Ta n/a 15 (23)
T1 n/a 9 (14)
T2 n/a 31 (48)
T3 n/a 4 (6)
T4 n/a 2 (3)
N+ , n/a 3 (5)
Grade
Low n/a 9 (14)
High n/a 55 (86)
‘, 4 subjects with concomitant Tis had T1 (n=2) and T2 (n=2) disease.
,, Subjects with T2 (n=1), T3 (=1) and T4 (n=1) disease and node positive.
doi:10.1371/journal.pone.0037797.t001
Table 2. Concentration of the biomarker proteins in voided
urine.
Non-cancer (%)
N=63
Cancer (%)
N=64
Urinary Proteins Mean (range) Mean (range)
CCl-18 (pg/ml) 4.81 (0–37.69) 637.39 (0–9523.04)
PAI-1 (ng/ml) 0.06 (0–0.64) 6.82 (0–125.26)
CD44 (ng/ml) 117.22 (16.08–616.3) 28.73 (16.67–344.04)
BTA (U/ml) 14.54 (0.5–36.87) 1630.55 (0–24865.4)
doi:10.1371/journal.pone.0037797.t002
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CCL18 clearly outperformed the other biomarkers, including
BTA, as a target protein for BCa detection by urinalysis. The
inclusion of additional markers (e.g., PAI-1 and CD44) to a
multiplex panel may not increase the predictive power significantly
(AUC 0.919 vs. 0.938), but their addition may make the model
more robust to errors thus illustrating the benefit of a multiplex
assay to diagnose BCa.
CCL18 is a member of the cytokine family of secreted proteins
involved in immunoregulatory and inflammatory processes.
CCL18 is thought to promote the invasiveness of cancer cells by
triggering integrin clustering and enhancing their adherence to the
extracellular matrix, and a receptor (PITPNM3) for this cytokine
has been recently identified [10]. A range of cytokines and their
receptors are known to be aberrantly expressed in tumor cells and
so it is conceivable that CCL18 can act in a paracrine fashion
during tumor initiation/establishment. As a biomarker of malig-
nant disease, CCL18 has been reported to be indicative of ovarian
[11,12] and cervical cancer [13]. A proteomics approach identified
elevated serum CCL18 as correlated with ovarian cancer, and this
finding was validated using ELISA in 535 samples. In combination
with CXCL1, CCL18 monitoring outperformed CA125 as a
circulating ovarian cancer biomarker [12]. A study analyzing
differential gene expression in 33 solid tissue samples identified
CCL18 as one of twenty transcripts significantly over-expressed in
invasive cervical cancers [13].
PAI-1 is a member of the serine proteinase inhibitor super
family and is the principal inhibitor of tissue plasminogen activator
(tPA) and urokinase (uPA), thus it regulates fibrinolysis [14]. PAI-1
is considered to be a multifunctional protein, which can also
modulate tumor cell growth and migration, angiogenesis and cell
adhesion [15,16]. Results from different human cancers have
demonstrated that the levels of tPA or uPA are significantly higher
in cancerous tissue relative to corresponding normal tissue [17–
19]. Hudson et al. reported that both non-invasive and invasive
human BCa cell lines produce PAI-1 [20], and elevated PAI-1
gene and protein expression in tissues and plasma has been
observed in BCA patients with a poor prognosis [21]. In a study
monitoring PAI-1 in tissues, serum and urine, significantly higher
levels in tissues and serum correlated with poor prognosis, but this
was not true for urinary PAI-1 [21]. In our study, we were looking
for the presence of BCa, and did not consider prognosis. We were
able to demonstrate that urinary PAI-1 was significantly elevated
in subjects with BCa (6.82 vs. 0.06, p,0.0001), however, in
multivariate analysis, PAI-1 was not an independent predictor of
BCa. PAI-1 may not be a powerful stand-alone biomarker for BCa
detection, but further investigation is needed to determine if it
adds value to multiple biomarker panels.
Figure 1. Comparison of urine concentrations of CCL18, PAI-1, CD44 and BTA between the bladder cancer and non-cancer groups.
Data are normalized to urinary creatinine. Median levels are depicted by horizontal lines. Significance (p,0.05) was assessed by the Wilcoxon rank
sum test.
doi:10.1371/journal.pone.0037797.g001
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cancer, including BCa. CD44 is a ubiquitously expressed
transmembrane glycoprotein that can interact with a variety of
ligands, e.g., hyaluronic acid synthases, and is involved in cell-cell
interactions, cell adhesion and migration [22]. Transcripts for this
gene undergo complex alternative splicing resulting in a myriad of
mRNA and protein isoforms with functional diversity, and this
makes it difficult to achieve consensus on which CD44 targets are
valid biomarkers. Klatte et al. demonstrated that absent CD44v6
expression in excised tissue is an independent adverse predictor of
BCa recurrence and overall survival [23], and over-expression of
CD44V8-10 in exfoliated urothelial cells has been reported to be
an independent prognostic predictor in patients with BCa [24].
We previously developed a sandwich-ELISA assay that measured
the CD44v6 protein isoform protein in urothelial cell lysates. In a
study of 65 cases, the sandwich-ELISA assay achieved 81%
sensitivity and 100% specificity for BCa diagnosis [25]. In line with
those findings, a study was able to associate soluble CD44v6
mRNA in cancer patient urine with BCa [26]. Our urothelial cell
Figure 2. Receiver operating characteristic (ROC) curves for urinary CCL18, PAI-1, CD44 and BTA. Based on the area under the ROC
curve (AUROC), Youden Index cutoff values that maximized the sum of sensitivity and specificity were determined for each biomarker (diamond).
Table provides performance values for each biomarker.
doi:10.1371/journal.pone.0037797.g002
Table 3. Logistic regression analysis of biomarkers in voided
urine.
Variable Coefficient Odds Ratio 95% C.I. p-value
CCL18 2.91 18.31 4.95–67.70 ,0.0001
CD44 23.25 0.039 0.004–0.35 0.0036
PAI-1 20.72 0.48 0.096–2.44 0.38
BTA 1.86 6.43 1.86–22.21 0.0033
doi:10.1371/journal.pone.0037797.t003
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transcripts may have value in clinical evaluation, but soluble
urinary CD44 protein does not seem to be a promising diagnostic
biomarker.
We recognize that our study has several limitations. First as a
tertiary care facility, we tend to see more high-grade, high-stage
disease, which is reflected in our study cohort. To confirm the
robustness of CCL18, subsequent studies must assess larger
cohorts that include subjects with low-grade, low-stage disease.
Second, processed, banked urines were analyzed. Urines were
centrifuged and separated into cellular pellet and supernatant
prior to storage at 280uC. It is feasible that freshly voided urine
samples may provide different results, and it is fresh urine that
would be the material used for point-of-care assays. We are
currently investigating the performance of selected biomarkers in
urines processed via a number of different protocols, including
freshly voided urines. Next, the sensitivity of VUC in our cohort of
predominantly high-grade (grade 3) disease (28%) was lower than
would be expected. This calls into question the known inter-
observer variability of interpreting VUC. In subsequent studies, we
will utilize two cytopathologists to interpret these results.
Furthermore, it is uncertain how the protein composition of the
urine supernatant may change during frozen storage. The number
of freeze-thaw cycles was kept to 1–2 by dividing the urine
supernatant into multiple small aliquots. Lastly, our sample size of
127 is small and the two groups that comprised the 127 subjects
were relatively homogeneous, i.e. either active cancer, or control
cases with no active cancer, no history of cancer, no urinary tract
infection, no urolithiasis, and no gross hematuria. Thus we were
not able to assess sensitivity/specificity of our biomarkers among
different stages/grades. The specificity of promising biomarkers
such as CCL18 needs to be tested in cohorts that are known to be
problematic with other urine-based assays (e.g., hematuria, urinary
tract infection, stones and voiding dysfunction). As we refine our
diagnostic molecular signatures and select specific targets for
nucleic acid-based or immune-based assay development, our
findings will be confirmed in large, prospective and multicenter
collaborative phase 2 and 3 trials consisting of subjects not only
with BCa, but with urinary tract infection, urolithiasis, gross
hematuria and voiding symptoms.
The development of urine-based bladder cancer biomarkers
would be of tremendous benefit to both patients and healthcare
systems. We have demonstrated in a preliminary study that
elevated urinary concentration of CCL18 protein is strongly
associated with the presence of BCa. Furthermore, the combina-
tion of CCL18, PAI-1 and CD44 may not increase the predictive
power of CCL18 significantly, but may make the model more
robust to errors. Larger, prospective studies are needed to
determine the potential role of CCL18 in the evaluation of
patients who are at risk of BCa.
Materials and Methods
Patients and specimen processing
Under MD Anderson Cancer Center Orlando Institutional
Review Board approval and informed written consent, voided
urine samples, and associated clinical information were prospec-
tively collected. The study cohort consisted of 63 individuals with
no previous history of urothelia carcinoma, gross hematuria, active
urinary tract infection or urolithiasis, and 64 individuals with
newly diagnosed urothelial carcinoma. Patients with known renal
disease or documented renal insufficiency were not enrolled.
According to the International Consensus Panel on Bladder
Tumor Markers [27], this cohort served as a phase II (validation
study). Data is reported using the STARD criteria [28]. In our
cancer group, axial imaging of the abdomen and pelvis and
cystoscopy were performed, and urothelial cell carcinoma was
confirmed by histological examination of excised tissue. Pertinent
information on clinical presentation, staging, histologic grading
[29,30] and outcome were recorded (Table 1).
Prior to any type of therapeutic intervention, 50–100 mL of
voided urine was obtained from each subject. Fifty milliliters of
urine was used for clinical laboratory analyses per standard
procedures. The remaining urine aliquot was assigned a unique
identifying number before immediate laboratory processing. Each
urine sample was centrifuged at 6006 g4 uC for 5 min. The
supernatant was decanted and aliquoted, while the urinary pellet
was snap frozen. Both the supernatant and pellet were stored at
280uC prior to analysis. Aliquots of urine supernatants were
thawed and analyzed for protein content using a Pierce 660-nm
Protein Assay Kit (Thermo Fisher Scientific Inc., Waltham, MA,
USA). Protein concentrations were measured using the NanoDrop
spectrophotometer (ND-1000, ThermoScientific, Wilmington,
DE, USA).
Urine Based Enzyme-Linked Immunosorbent Assay
(ELISA)
Levels of human C-C motif chemokine 18 (CCL18), also known
as CCL18 (Cat # ab100620 Abcam, Cambridge, MA, USA),
human Plasminogen Activator Inhibitor 1 (PAI-1, Cat# EA-0207
Signosis Inc., Sunnyvale, CA, USA), and CD44 (Cat # ab 45912
Abcam, Cambridge, MA, USA) were monitored in urine samples
using enzyme-linked immunosorbent assay. Commercially avail-
able ELISA assays were also used to measure levels of urinary
hemoglobin (Cat#E88-135 Bethyl Laboratories Inc., Montgom-
ery, TX, USA), and BTA (BTA-Trak Ca# 662150 Polymedco
Inc. Cortlandt Manor, NY, USA). Readers of these assays were
blinded as to disease status. All assays were conducted according to
Figure 3. Receiver operating characteristic (ROC) curve to plot
the performance of the combination of CCL18, PAI-1 and CD44
biomarkers. Based on the area under the ROC curve (AUROC), Youden
Index cutoff values that maximized the sum of sensitivity and specificity
were determined. Data within the figure provide performance values.
PPV, positive predictive value. NPV, negative predictive value.
doi:10.1371/journal.pone.0037797.g003
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using purified standards for each protein assessed. Curve fitting
was accomplished by either linear or four-parameter logistic
regression following manufacturer’s instructions.
Creatinine Assay
Creatine is converted non-enzymatically to the metabolite
creatinine, which diffuses into the blood and is excreted into the
urine by the kidneys at a constant rate. Consequently, urinary
creatinine is a useful tool for normalizing the levels of other
molecules found in urine [31,32]. Our preliminary results (not
shown) demonstrated that due to the hematuria (microscopic or
gross blood in the urine), which contains elevated levels of
proteins, protein would not be a good marker for normalization.
Thus, the concentrations of all monitored proteins (CCL18, PAI-
1, CD44 and BTA) were normalized to urinary creatinine and
these concentrations were reported as a ratio relative to urinary
creatinine values. The creatinine assay was conducted according
to the manufacturer’s instructions (Cat# KGE005 R&D Systems
Inc., Minneapolis, MN, USA). Briefly, urine supernatants were
thawed, diluted with distilled water and treated with alkaline
picrate solution. Treated samples were measured on a microplate
reader (Bio-tek, Synergy
TM HT, VT) at a wavelength of 490 nm.
A standard curve using purified standards was generated by
regression analysis using four-parameter logistic curve-fit, and
signal intensities were converted to concentrations.
Statistical Analysis
The association between each biomarker and BCa was tested
using the Wilcoxon rank sum test. Nonparametric receiver
operating characteristic (ROC) curves in which the value for
sensitivity is plotted against false-positive rate (1-specificity) were
generated. We defined a diagnostic test as positive or negative for
BCa detection using a cutoff value. The optimal cutoff (Youden
index) was selected to maximize the sum of the sensitivity and
specificity [33]. The accuracy of a biomarker to predict the
presence of BCa was defined as the average of the sensitivity and
the specificity. To assess the independent association between
biomarkers and BCa, logistic regression analysis was performed
with BCa status (yes vs. no) as the response variable, and CCL18,
PAI-1, CD44, BTA concentrations as the explanatory variables.
Statistical significance in this study was set at p,0.05 and all
reported p values were 2-sided. All analyses were performed with
SAS software version 9.1.3.
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